Bristol's High Profile TYK2 Inhibitor Disappoints In Ulcerative Colitis
Deucravacitinib is an oral drug in development for a wide range of autoimmune conditions, including psoriasis and psoriatic arthritis.
You may also be interested in...
Without disclosing data, Nimbus announced positive Phase IIb results for NDI-034858 in psoriasis. The company plans to initiate a Phase III trial next year.
Remission rates with existing therapies leave much room for improvement, so a variety of treatments are needed – leaving major players attempting to carve unique paths in a crowded market.
The company has admitted making mistakes in its R&D, but must now convince investors that its new multi-modality approach will pay off.